graph Evidence gap map comparisons
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane ganitumab plus endocrine therapy
Comparator:  vs exemestane plus ridaforolimus;   vs endocrine therapy; 
Risk of bias:  low;   some concerns;   high;  NA;